CME Information: Diabetes from the Perspective of the Cardiologist: An Evolving Paradigm
Diabetes from the Perspective of the Cardiologist: An Evolving Paradigm
At the conclusion of this activity, participants will be able to:
- Discuss the connections between the etiology and the pathophysiology of various components of the cardiometabolic syndrome and the development of cardiovascular disease in people with type 2 diabetes
- Describe the rationale for evaluating the cardiovascular impact of antidiabetes medications, and key data from recent cardiovascular outcomes trials of antidiabetes medications
- Discuss how antidiabetes medications with demonstrated cardiovascular benefits can be integrated into guideline-driven glycemic control programs for people with type 2 diabetes
- Identify methods whereby cardiologists can spearhead coordination of care among various providers for a person with both cardiac disease and type 2 diabetes to optimize outcomes for both conditions
This activity is supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC, and Novo Nordisk Inc.
The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENTS
Live Internet Activity
Albert Einstein College of Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Albert Einstein College of Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
DATE OF RELEASE/EXPIRATION
Live Internet Activity
July 29, 2019 from 11:00 AM ET – 1:00 PM ET
The enduring material will be available from July 29, 2019 to January 29, 2020.
This activity is intended for cardiologists and cardiology allied health care professionals (NPs, PAs, etc.) involved in the care of patients with cardiovascular disease and type 2 diabetes; other health care professionals involved in the care of patients with cardiovascular disease and type 2 diabetes, such as internal medicine and primary care clinicians, may also benefit from this education.
ESTIMATED TIME TO COMPLETE
This activity consists of two sessions, which should take approximately 2 hours to complete.
METHOD OF PARTICIPATION
There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 2 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.
HARDWARE / SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
|Seth J. Baum, MD, FACC, FACPM, FAHA, FNLA, FASPC||
Consulting Fee: Sanofi, Amgen, Gerson Lehrman Group, Guidepoint Global, Regeneron, Novo Nordisk, Akcea
Speaker’s Bureau: Amgen, Boehringer Ingelheim/Lilly, Novo Nordisk, Akcea, Regeneron
Contracted Research: NGM Biopharmaceuticals, Inc., Axcella Health, Inc., GENFIT, Regeneron Pharmaceuticals, Inc., Novartis, HighTide Biopharma Pty. Ltd., Novo Nordisk, CymaBay Therapeutics, Inc., Akcea Therapeutics, Inc., Sanofi, Esperion Therapeutics, Inc.
Ownership Interest: Vital Remedy (spouse)
Scientific Advisory Board: Sanofi, Amgen, Regeneron, Akcea, Novartis, AstraZeneca
|Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE||
Research Grant: Amgen, AZ, BMS, BI, Gan & Lee, Hamni, Janssen, Lexicon, Merck, Mylan, Novo Nordisk, Sanofi
Advisory/Consultant: Aegerion, Amarin, Amgen, AZ, BI, Gilead, Intarcia, Lilly, Janssen, Merck, Merck-Pfizer, Novo Nordisk, Regeneron, Sanofi, Target
Speaker’s Bureau: Aegerion, Amarin, Amgen, AZ, BI-Lilly, Janssen, Merck, Novo Nordisk, Sanofi, Regeneron
|Mikhail N. Kosiborod, MD||
Consulting Fee: Amarin, Amgen, Applied Therapeutics, Astra Zeneca, Bayer, Boehringer Ingelheim, Eisai, GlaxoSmithKline, Glytec, Intarcia, Janssen, Merck (Diabetes), Novartis, Novo Nordisk, Sanofi
Contracted Research: AstraZeneca, Boehringer Ingelheim
Other Research Support: AstraZeneca
Will discuss unlabeled uses of SGLT-2 Inhibitors which is used with diet and exercise to lower blood sugar in adults with type 2 diabetes and GLP-1 Receptor Agonists which is used to help control how the pancreas works.
The following are additional on-label indications for the following drugs:
Empagliflozin – Reduce risk of cardiovascular death in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD)
Canagliflozin – Reduce risk of major adverse cardiovascular events (MACE) events in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD)
Liraglutide – Reduce risk of major adverse cardiovascular events (MACE) in patients with type 2 diabetes and atherosclerotic cardiovascular disease (ASCVD)
The unlabeled uses of SGLT-2 Inhibitors and GLP-1 Receptor Agonists to be discussed are for the prevention of heart failure and chronic kidney disease in patients with type 2 diabetes.
|Mark Menegus, MD||Has nothing to disclose relevant to this activity.|
|PlatformQ Health Education, LLC||Disclosures|
|Anne Roc, Medical Director||Has nothing to disclose relevant to this activity.|
|Elizabeth del Nido, Senior Program Manager||Has nothing to disclose relevant to this activity.|
Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to firstname.lastname@example.org.
For issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.
DISCLAIMERS (if applicable):
The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, CardioCareLive, PlatformQ Health Education, LLC or the program grantors. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.